PVP Ventures Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
PVP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
PVP Ventures has confirmed to the stock exchanges that during the quarter ended 30th June 2025, there was no deviation or variation in the use of proceeds from its Non-Convertible Debenture (NCD) issue. The company had raised Rs. 150 crore through a private placement of NCDs (Series A and Series B) on 11th April 2025. Out of this, Rs. 71.31 crore has been used towards the acquisition of Biohygea Global Pvt. Ltd. and Optimus Oncology Pvt. Ltd., including issue-related expenses. The remaining Rs. 78.50 crore is parked in a fixed deposit with HDFC Bank, and Rs. 18 lakh is held in an escrow account. The statement was reviewed by the Audit Committee and Board of Directors at their meeting on 20th August 2025.
This is a routine compliance filing that signals disciplined use of NCD proceeds as originally planned, with no misuse or unplanned diversions. For shareholders, it reassures that the Rs. 150 crore raised is being deployed toward stated strategic acquisitions, which is mildly positive for governance perception but unlikely to move the stock price on its own.